Phase 2 Stomach Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a specific type of stomach or gastroesophageal junction cancer (diffuse type, poorly cohesive, signet ring cell, or mixed type), confirmed by a tissue or cell sample — or people with certain genetic mutations (CDH1 and/or RHOA) regardless of cancer type.
• People who have already received at least one prior treatment for cancer that has spread or cannot be removed by surgery, and that treatment must have included two specific types of chemotherapy drugs (a platinum-based drug and a fluoropyrimidine).
• People who are reasonably active and able to carry out daily activities, as measured by a standard medical scoring system (ECOG score of 0 or 1).
• People aged 18 years or older.
• People whose blood counts, liver function, kidney function, heart function, and other laboratory results meet specific healthy thresholds set by the trial (confirm with trial site for exact values).
• People whose cancer can be seen and tracked on medical imaging scans, with scans completed within 28 days before starting the trial treatment.
• People whose tumour can be sampled with a fresh biopsy, which may include fluid from the abdomen if present.
• People whose heart's electrical activity (measured by an ECG) falls within a specific range — under 460 milliseconds for women and 450 milliseconds for men (this does not apply to people with certain heart conduction conditions).
• People who have recovered sufficiently from side effects of previous treatments before joining the trial.
• People who are willing and able to use effective contraception during the trial and for a period after the last dose, as the effects of the trial drugs on an unborn baby are not yet known (confirm with trial site for specific requirements).
• People who are able to understand the trial and are willing to sign a written consent form.

Who may not be able to join:

• People who have received cancer treatment within 3 weeks before the first trial dose, or within 5 half-lives of the previous drug, whichever is the shorter time period.
• People currently taking part in another clinical trial involving an experimental treatment.
• People who have had a different cancer diagnosis within the past two years, unless that cancer was a type with a very low risk of spreading or causing death (such as certain early-stage or non-invasive cancers — confirm with trial site for the full list of exceptions).
• People who have had major surgery within 4 weeks, or palliative radiation therapy within 1 week, before the first trial dose.
• People currently taking the blood-thinning medication warfarin (though switching to a different blood thinner may be possible — confirm with trial site).
• People who have previously been treated with a drug that directly targets FAK, MEK, or KRAS.
• People who have taken certain medications, supplements, herbal remedies, or foods known to interact with the trial drugs within 14 days before starting the trial (confirm with trial site for the specific list of substances to avoid).
• People with brain metastases that are currently causing symptoms and require steroid treatment or other active interventions — though people with previously treated and stable brain metastases who have stopped steroids for at least 4 weeks may be considered.
• People with an active hepatitis B, hepatitis C, or HIV infection that is being treated or requires treatment, including HIV patients on combination antiretroviral therapy.
• People with an active skin condition that required systemic (whole-body) treatment within the past year.
• People with a history of a serious muscle-breakdown condition called rhabdomyolysis.
• People with certain eye conditions, including a history of glaucoma, retinal vein blockage, certain retinal problems, uncontrolled high blood pressure or diabetes that could affect the eyes, high pressure inside the eye, or active corneal disorders that could affect monitoring during the trial (confirm with trial site for the full list).
• People with serious heart or lung conditions, including heart failure, a heart attack in the last 6 months, unstable heart rhythm, unstable chest pain, or severe breathing problems.
• People who are unable to swallow oral (tablet or capsule) medications.
• People with a known allergy to any of the inactive ingredients in the trial drugs (hydroxypropylmethylcellulose, mannitol, or magnesium stearate).
• People who are pregnant or currently breastfeeding, as the effects of the trial drugs on an unborn baby or nursing infant are not yet known.
• People with any other serious medical condition that the trial doctor considers would put them at too high a risk of harm from the trial treatment.

Important: Always verify eligibility with the trial site directly before applying.